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Serological markers of infection (antibodies or antigens) of
viruses that cause cancer are most often detected using
ELISA-based methodologies. In many cases, multiple mar-
kers of infection must be assessed to determine a final
sero-status. Volume requirements and costs of reagents
for single analyte ELISAs are high and studies which
include multiple viruses can require milliliters of plasma,
often not available from archived cohorts. Thus, we sought
to develop a Luminex
® bead-based customizable panel
initially including Hepatitis B Virus (HBV), Hepatitis C
Virus (HCV), Epstein-Barr Virus (EBV) and often the con-
comitant infection, Human Immunodeficiency Virus
(HIV) to reduce sample volume requirements, overall cost
and increase flexibility. Peptides, antigens and antibodies
were sourced from multiple manufacturers and tested for
suitability in this platform. Where necessary, suitable
reagents were designed and produced in-house. The HCV
assay multiplexes four HCV peptides designed to detect
antibodies raised to HCV Core (2), HCV NS4, HCV NS5
g e n er e g i o n s .T h eH B Va s s a ym u l t i p l e x e saH B Ve a r l y
antigen peptide, a recombinant HBV core protein and
either a recombinant HBV surface antigen or an antibody
specific for HBV surface antigen to assess HBV infection.
The EBV assay multiplexes peptides specific to viral capsid
antigen, EBNA-1 and early antigen (Cyto-Barr, Zuidhorn,
The Netherlands). HIV-1 assay development is ongoing
and the list of antigens to be included in the assay has not
been finalized. These assays can be run singly or with any
combination (multi-plex) of the above listed targets. Each
target has been independently validated using samples of
known molecular and serological status to determine
specificity (false positive versus false negative) and re-
evaluated under multiplex conditions to confirm assay
performance. In addition, where possible, samples were
assayed on commercial testing platforms as well as our
multiplex assay to assess concordance (94-99%). Depen-
dent on the panel selected and the expected antibody titers
in a particular population, plasma or serum volumes in the
range of 10 µL to 125 µL per subject would be required to
determine the HBV, HCV, EBV and/or HIV serostatus of
a subject. This assay platform is inherently flexible and the
benefits include amenability to expansion to include other
oncogenic viruses as well as screening large epidemiologi-
cal cohorts or smaller subsets of samples in an economical
and high throughput manner.
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